{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:43:53Z","timestamp":1793641433590,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Atomic Bomb Disease Institute, Nagasaki University and the Program of the Network-Type Joint Usage\/Research Center for Radiation Disaster Medical Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01954-9","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:56:14Z","timestamp":1747734974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples"],"prefix":"10.1186","volume":"25","author":[{"given":"Thi Nhung","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Mussazhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kurohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Dong","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Ha","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Minh Hanh","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Phu Thang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Tratsiakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Ngoc Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerkezhan","family":"Sailaubekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Phuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Son","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-8735","authenticated-orcid":false,"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"1954_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the united States: 2000\u20132018. Thyroid. 2022;32:560\u201370. https:\/\/doi.org\/10.1089\/thy.2021.0662.","journal-title":"Thyroid"},{"key":"1954_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM199801293380506","volume":"338","author":"MJ Schlumberger","year":"1998","unstructured":"Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297\u2013306. https:\/\/doi.org\/10.1056\/NEJM199801293380506.","journal-title":"N Engl J Med"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892\u20139. https:\/\/doi.org\/10.1210\/jc.2005-2838.","journal-title":"J Clin Endocrinol Metab"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A. clinicalguidelines@esmo.org EGCEa. ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33:674\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.009.","journal-title":"Ann Oncol"},{"key":"1954_CR6","doi-asserted-by":"publisher","first-page":"152243","DOI":"10.1016\/j.anndiagpath.2023.152243","volume":"69","author":"W Liu","year":"2024","unstructured":"Liu W, Jiang B, Xue J, Liu R, Wei Y, Li P. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy. Ann Diagn Pathol. 2024;69:152243. https:\/\/doi.org\/10.1016\/j.anndiagpath.2023.152243.","journal-title":"Ann Diagn Pathol"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"1109439","DOI":"10.3389\/fendo.2023.1109439","volume":"14","author":"C Meng","year":"2023","unstructured":"Meng C, Song J, Long W, Mu Z, Sun Y, Liang J, Lin Y. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2023;14:1109439. https:\/\/doi.org\/10.3389\/fendo.2023.1109439.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"549882","DOI":"10.3389\/fonc.2020.549882","volume":"10","author":"Y Luo","year":"2020","unstructured":"Luo Y, Jiang H, Xu W, Wang X, Ma B, Liao T, Wang Y. Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Front Oncol. 2020;10:549882. https:\/\/doi.org\/10.3389\/fonc.2020.549882.","journal-title":"Front Oncol"},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.119.227652","volume":"61","author":"J Liu","year":"2020","unstructured":"Liu J, Liu R, Shen X, Zhu G, Li B, Xing M. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med. 2020;61:177\u201382. https:\/\/doi.org\/10.2967\/jnumed.119.227652.","journal-title":"J Nucl Med"},{"key":"1954_CR10","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1007\/s00259-022-05820-x","volume":"49","author":"J Cao","year":"2022","unstructured":"Cao J, Zhu X, Sun Y, Li X, Yun C, Zhang W. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2022;49:3470\u201381. https:\/\/doi.org\/10.1007\/s00259-022-05820-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"e3206","DOI":"10.1210\/clinem\/dgac305","volume":"107","author":"MH Soe","year":"2022","unstructured":"Soe MH, Chiang JM, Flavell RR, Khanafshar E, Mendoza L, Kang H, Liu C. Non-iodine-avid disease is highly prevalent in distant metastatic differentiated thyroid cancer with papillary histology. J Clin Endocrinol Metab. 2022;107:e3206\u201316. https:\/\/doi.org\/10.1210\/clinem\/dgac305.","journal-title":"J Clin Endocrinol Metab"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"959089","DOI":"10.3389\/fendo.2022.959089","volume":"13","author":"S Huang","year":"2022","unstructured":"Huang S, Qi M, Tian T, Dai H, Tang Y, Huang R. Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases. Front Endocrinol (Lausanne). 2022;13:959089. https:\/\/doi.org\/10.3389\/fendo.2022.959089.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"930180","DOI":"10.3389\/fendo.2022.930180","volume":"13","author":"J Chai","year":"2022","unstructured":"Chai J, Zhang R, Zheng W, Zhang G, Jia Q, Tan J, Meng Z, Wang R. Predictive value of clinical and pathological characteristics for metastatic radioactive iodine-refractory differentiated thyroid carcinoma: a 16-year retrospective study. Front Endocrinol (Lausanne). 2022;13:930180. https:\/\/doi.org\/10.3389\/fendo.2022.930180.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.2147\/OTT.S308910","volume":"14","author":"T Anekpuritanang","year":"2021","unstructured":"Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The association between radioiodine refractory in papillary thyroid carcinoma, sodium\/iodide symporter expression, and BRAF (V600E) mutation. Onco Targets Ther. 2021;14:3959\u201369. https:\/\/doi.org\/10.2147\/OTT.S308910.","journal-title":"Onco Targets Ther"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12022-024-09801-8","volume":"35","author":"ED Rossi","year":"2024","unstructured":"Rossi ED, Pantanowitz L. Focal tall cell change in papillary thyroid carcinoma: lessons learned from practices adopting rigid criteria (Height to width ratio of 3). Endocr Pathol. 2024;35:80\u20131. https:\/\/doi.org\/10.1007\/s12022-024-09801-8.","journal-title":"Endocr Pathol"},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1245\/s10434-019-07444-2","volume":"26","author":"PJ Bongers","year":"2019","unstructured":"Bongers PJ, Kluijfhout WP, Verzijl R, Lustgarten M, Vermeer M, Goldstein DP, Devon K, Rotstein LE, Asa SL, Brierley JD, et al. Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease. Ann Surg Oncol. 2019;26:2533\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07444-2.","journal-title":"Ann Surg Oncol"},{"key":"1954_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/jcp.2010.083956","volume":"64","author":"Z Liu","year":"2011","unstructured":"Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, Taniguchi E, Mori I. Loss of cellular polarity\/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol. 2011;64:325\u20139. https:\/\/doi.org\/10.1136\/jcp.2010.083956.","journal-title":"J Clin Pathol"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/jcp.2004.017889","volume":"57","author":"K Kakudo","year":"2004","unstructured":"Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol. 2004;57:1041\u20136. https:\/\/doi.org\/10.1136\/jcp.2004.017889.","journal-title":"J Clin Pathol"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00268-021-06070-y","volume":"45","author":"H Lindfors","year":"2021","unstructured":"Lindfors H, Ihre Lundgren C, Zedenius J, Juhlin CC, Shabo I. The clinical significance of lymph node ratio and Ki-67 expression in papillary thyroid cancer. World J Surg. 2021;45:2155\u201364. https:\/\/doi.org\/10.1007\/s00268-021-06070-y.","journal-title":"World J Surg"},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s00268-010-0746-3","volume":"34","author":"Y Ito","year":"2010","unstructured":"Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg. 2010;34:3015\u201321. https:\/\/doi.org\/10.1007\/s00268-010-0746-3.","journal-title":"World J Surg"},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12022-023-09769-x","volume":"34","author":"J Metovic","year":"2023","unstructured":"Metovic J, Cabutti F, Osella-Abate S, Orlando G, Tampieri C, Napoli F, Maletta F, Daniele L, Volante M, Papotti M. Clinical and pathological features and gene expression profiles of clinically aggressive papillary thyroid carcinomas. Endocr Pathol. 2023;34:298\u2013310. https:\/\/doi.org\/10.1007\/s12022-023-09769-x.","journal-title":"Endocr Pathol"},{"key":"1954_CR22","doi-asserted-by":"publisher","unstructured":"Coca-Pelaz A, Rodrigo JP, Shah JP, Nixon IJ, Hartl DM, Robbins KT, Kowalski LP, Makitie AA, Hamoir M, Lopez F, et al. Recurrent differentiated thyroid cancer: the current treatment options. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15102692.","DOI":"10.3390\/cancers15102692"},{"key":"1954_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","volume":"97","author":"EL Mazzaferri","year":"1994","unstructured":"Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418\u201328. https:\/\/doi.org\/10.1016\/0002-9343(94)90321-2.","journal-title":"Am J Med"},{"key":"1954_CR24","doi-asserted-by":"publisher","unstructured":"Otsubo C, Mussazhanova Z, Kurohama H, Shalgimbayeva G, Ueki N, Matsuoka Y, Madiyeva M, Sato S, Yamashita H, Nakashima M. A new indicator to differentiate thyroid follicular inclusions in cervical lymph nodes from patients with thyroid cancer. Int J Mol Sci. 2022;24. https:\/\/doi.org\/10.3390\/ijms24010490.","DOI":"10.3390\/ijms24010490"},{"key":"1954_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/cen.14567","volume":"95","author":"T Nakao","year":"2021","unstructured":"Nakao T, Matsuse M, Saenko V, Rogounovitch T, Tanaka A, Suzuki K, Higuchi M, Sasai H, Sano T, Hirokawa M, et al. Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas. Clin Endocrinol (Oxf). 2021;95:790\u20139. https:\/\/doi.org\/10.1111\/cen.14567.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1089\/thy.2018.0695","volume":"29","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, et al. TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid. 2019;29:1105\u201314. https:\/\/doi.org\/10.1089\/thy.2018.0695.","journal-title":"Thyroid"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000501097","volume":"86","author":"M Hirokawa","year":"2019","unstructured":"Hirokawa M, Matsuda K, Kudo T, Higuchi M, Suzuki A, Takada N, Nakashima M, Miyauchi A. Cribriform-morular variant of papillary thyroid carcinoma shows high Ki-67 labeling indices, despite its excellent prognosis. Pathobiology. 2019;86:248\u201353. https:\/\/doi.org\/10.1159\/000501097.","journal-title":"Pathobiology"},{"key":"1954_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simoes M, Tallini G, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022;33:27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3.","journal-title":"Endocr Pathol"},{"key":"1954_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2009.02.043","volume":"281","author":"Y Bai","year":"2009","unstructured":"Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, Liu Z, Mori I, Miyauchi A, Zhou G. Loss of cellular polarity\/cohesiveness in the invasive front of papillary thyroid carcinoma and Periostin expression. Cancer Lett. 2009;281:188\u201395. https:\/\/doi.org\/10.1016\/j.canlet.2009.02.043.","journal-title":"Cancer Lett"},{"key":"1954_CR30","doi-asserted-by":"publisher","unstructured":"Cree IA, Tan PH, Travis WD, Wesseling P, Yagi Y, White VA, Lokuhetty D, Scolyer RA. Counting mitoses: SI(ze) matters! Mod Pathol. 2021;34:1651\u20137. https:\/\/doi.org\/10.1038\/s41379-021-00825-7.","DOI":"10.1038\/s41379-021-00825-7"},{"key":"1954_CR31","doi-asserted-by":"publisher","unstructured":"Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30. https:\/\/doi.org\/10.1530\/ERC-22-0293.","DOI":"10.1530\/ERC-22-0293"},{"key":"1954_CR32","doi-asserted-by":"publisher","unstructured":"Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017; 27:751\u20136; https:\/\/doi.org\/10.1089\/thy.2017.0102","DOI":"10.1089\/thy.2017.0102"},{"key":"1954_CR33","unstructured":"Posit Team. RStudio: integrated development environment for R. 2023."},{"key":"1954_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-022-03146-0","volume":"78","author":"C Pizzimenti","year":"2022","unstructured":"Pizzimenti C, Fiorentino V, Ieni A, Martini M, Tuccari G, Lentini M, Fadda G. Aggressive variants of follicular cell-derived thyroid carcinoma: an overview. Endocrine. 2022;78:1\u201312. https:\/\/doi.org\/10.1007\/s12020-022-03146-0.","journal-title":"Endocrine"},{"key":"1954_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/PAP.0000000000000184","volume":"25","author":"MC Nath","year":"2018","unstructured":"Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol. 2018;25:172\u20139. https:\/\/doi.org\/10.1097\/PAP.0000000000000184.","journal-title":"Adv Anat Pathol"},{"key":"1954_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jclinpath-2013-201626","volume":"66","author":"Z Baloch","year":"2013","unstructured":"Baloch Z, LiVolsi VA, Tondon R. Aggressive variants of follicular cell derived thyroid carcinoma; the so called \u2018real thyroid carcinomas\u2019. J Clin Pathol. 2013;66:733\u201343. https:\/\/doi.org\/10.1136\/jclinpath-2013-201626.","journal-title":"J Clin Pathol"},{"key":"1954_CR37","doi-asserted-by":"publisher","unstructured":"Nilsson JN, Siikanen J, Condello V, Jatta K, Saini R, Hedman C, Ihre Lundgren C, Juhlin CC. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. Eur Thyroid J. 2023;12. https:\/\/doi.org\/10.1530\/ETJ-23-0099.","DOI":"10.1530\/ETJ-23-0099"},{"key":"1954_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40644-020-00378-z","volume":"21","author":"LN Ha","year":"2021","unstructured":"Ha LN, Iravani A, Nhung NT, Hanh NTM, Hutomo F, Son MH. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma. Cancer Imaging. 2021;21:8. https:\/\/doi.org\/10.1186\/s40644-020-00378-z.","journal-title":"Cancer Imaging"},{"key":"1954_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10147-013-0620-z","volume":"19","author":"S Wei","year":"2014","unstructured":"Wei S, Gao M, Zhao C, Pan Y, Li H, Li J, Li X. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. Int J Clin Oncol. 2014;19:800\u20134. https:\/\/doi.org\/10.1007\/s10147-013-0620-z.","journal-title":"Int J Clin Oncol"},{"key":"1954_CR40","doi-asserted-by":"publisher","unstructured":"Kim MJ, Kim JK, Kim GJ, Kang SW, Lee J, Jeong JJ, Chung WY, Kim D, Nam KH. TERT promoter and BRAF V600E mutations in papillary thyroid cancer: A Single-Institution experience in Korea. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14194928.","DOI":"10.3390\/cancers14194928"},{"key":"1954_CR41","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493\u2013501. https:\/\/doi.org\/10.1001\/jama.2013.3190.","journal-title":"JAMA"},{"key":"1954_CR42","doi-asserted-by":"publisher","first-page":"9959649","DOI":"10.1155\/2022\/9959649","volume":"2022","author":"X Wei","year":"2022","unstructured":"Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J. Risk and prognostic factors for BRAF(V600E) mutations in papillary thyroid carcinoma. Biomed Res Int. 2022;2022:9959649. https:\/\/doi.org\/10.1155\/2022\/9959649.","journal-title":"Biomed Res Int"},{"key":"1954_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","volume":"67","author":"J Yang","year":"2020","unstructured":"Yang J, Gong Y, Yan S, Chen H, Qin S, Gong R. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine. 2020;67:44\u201357. https:\/\/doi.org\/10.1007\/s12020-019-02117-2.","journal-title":"Endocrine"},{"key":"1954_CR44","doi-asserted-by":"publisher","unstructured":"Park J, Lee S, Kim K, Park H, Ki CS, Oh YL, Shin JH, Kim JS, Kim SW, Chung JH, et al. TERT promoter mutations and the 8th edition TNM classification in predicting the survival of thyroid cancer patients. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13040648.","DOI":"10.3390\/cancers13040648"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01954-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:56:18Z","timestamp":1747734978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01954-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01954-9","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of the 108 Military Central Hospital (5199\/GCN-BV) and the Institutional Ethical Committee for Medical Research at Nagasaki University (#15062617-6). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"134"}}